Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation
Clinical trial NCT04858958 · COMPLETED
Trial details
- NCT number
- NCT04858958
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-10
- Primary completion
- 2024-12-05
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.